20000804
 Dutch Firm Buys California Drug Maker   By By James M. Dorsey, The Wall Street Journal,  Aug 4, 2000  DSM also agreed to assume 55 million euros in Catalytica debt. It plans to pay for the acquisition and Catalytica debt either by issuing bonds or through short-term loans, according to Peter Elverding, chairman of DSM's management board. Catalytica said its shareholders would receive $9 to $10 in cash per share as well as shares in the new company to be formed by the spun-off divisions.   
